Meta-mining of Neuroblastoma and Neuroblast Gene Expression Profiles Reveals Candidate Therapeutic Compounds

Purpose: Neuroblastoma is a heterogeneous childhood tumor with poor survival outcome for the aggressive type despite intensive multimodal therapies. In this study, we aimed to identify new treatment options for neuroblastoma based on integrative genomic analysis. Experimental Design: The Connectivity Map is a database comprising expression profiles in response to known therapeutic compounds. This renders it a useful tool in the search for potential therapeutic compounds based on comparison of gene expression profiles of diseased cells and a database of profiles in response to known therapeutic compounds. We have used this strategy in the search for new therapeutic molecules for neuroblastoma based on data of an integrative meta-analysis of gene copy number and expression profiles from 146 primary neuroblastoma tumors and normal fetal neuroblasts. Results: In a first step, a 132-gene classifier was established that discriminates three major genomic neuroblastoma subgroups, reflecting inherent differences in gene expression between these subgroups. Subsequently, we screened the Connectivity Map database using gene lists generated by comparing expression profiles of fetal adrenal neuroblasts and the genomic subgroups of neuroblastomas. A putative therapeutic effect was predicted for several compounds of which six were empirically tested. A significant reduction in cell viability was shown for five of these molecules: 17-allylamino-geldanamycin, monorden, fluphenazine, trichostatin, and rapamycin. Conclusions: This proof-of-principle study indicates that an integrative genomic meta-analysis approach with inclusion of neuroblast data enables the identification of promising compounds for treatment of children with neuroblastoma. Further studies are warranted to explore in detail the therapeutic potential of these compounds.

[1]  R. Arceci,et al.  Phase I Pharmacokinetic and Pharmacodynamic Study of 17-N-Allylamino-17-Demethoxygeldanamycin in Pediatric Patients with Recurrent or Refractory Solid Tumors: A Pediatric Oncology Experimental Therapeutics Investigators Consortium Study , 2007, Clinical Cancer Research.

[2]  S. Ishii,et al.  Expression profiling using a tumor-specific cDNA microarray predicts the prognosis of intermediate risk neuroblastomas. , 2005, Cancer cell.

[3]  A. Salminen,et al.  Radicicol but not geldanamycin evokes oxidative stress response and efflux protein inhibition in ARPE-19 human retinal pigment epithelial cells. , 2008, European journal of pharmacology.

[4]  D Catchpoole,et al.  Oligonucleotide microarray analysis of gene expression in neuroblastoma displaying loss of chromosome 11q. , 2004, Carcinogenesis.

[5]  Jo Vandesompele,et al.  RTPrimerDB: the portal for real-time PCR primers and probes , 2008, Nucleic Acids Res..

[6]  Frank Speleman,et al.  ArrayCGH‐based classification of neuroblastoma into genomic subgroups , 2007, Genes, chromosomes & cancer.

[7]  John M. Maris,et al.  Identification of ALK as a major familial neuroblastoma predisposition gene , 2008, Nature.

[8]  Paul A Clemons,et al.  The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease , 2006, Science.

[9]  Jean YH Yang,et al.  Bioconductor: open software development for computational biology and bioinformatics , 2004, Genome Biology.

[10]  J. Trent,et al.  Chromosome localization in normal human cells and neuroblastomas of a gene related to c-myc , 1984, Nature.

[11]  Abraham Weizman,et al.  Characterization of phenothiazine-induced apoptosis in neuroblastoma and glioma cell lines , 2007, Journal of Molecular Neuroscience.

[12]  H. Aburatani,et al.  Gene expression profiling and identification of novel prognostic marker genes in neuroblastoma , 2004, Genes, chromosomes & cancer.

[13]  J. Joseph,et al.  Complex molecular mechanisms cooperate to mediate histone deacetylase inhibitors anti-tumour activity in neuroblastoma cells , 2008, Molecular Cancer.

[14]  M. E. Robinson,et al.  Favorable Neuroblastoma Genes and Molecular Therapeutics of Neuroblastoma , 2004, Clinical Cancer Research.

[15]  Gudrun Schleiermacher,et al.  Gene expression profiling of 1p35–36 genes in neuroblastoma , 2004, Oncogene.

[16]  Todd R Golub,et al.  Expression-based screening identifies the combination of histone deacetylase inhibitors and retinoids for neuroblastoma differentiation , 2008, Proceedings of the National Academy of Sciences.

[17]  Bernd Giese,et al.  Targeting phosphoinositide 3-kinase: moving towards therapy. , 2008, Biochimica et biophysica acta.

[18]  Sreenath V. Sharma,et al.  Targeting of the protein chaperone, HSP90, by the transformation suppressing agent, radicicol , 1998, Oncogene.

[19]  K. Mills,et al.  Heat shock protein 90 inhibition is cytotoxic to primary AML cells expressing mutant FLT3 and results in altered downstream signalling , 2008, British journal of haematology.

[20]  Roland Eils,et al.  Prediction of clinical outcome and biological characterization of neuroblastoma by expression profiling , 2004 .

[21]  R. Arceci.  Integrative Genomics Identifies Distinct Molecular Classes of Neuroblastoma and Shows That Multiple Genes Are Targeted by Regional Alterations in DNA Copy Number , 2008 .

[22]  S. Minucci,et al.  Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer , 2006, Nature Reviews Cancer.

[23]  Andrew G. Hall,et al.  Identification of candidate genes involved in neuroblastoma progression by combining genomic and expression microarrays with survival data , 2007, Oncogene.

[24]  Stuart L Schreiber,et al.  Identification of a small-molecule inhibitor of class Ia PI3Ks with cell-based screening. , 2007, Chemistry & biology.

[25]  Michael F. Clarke,et al.  Applying the principles of stem-cell biology to cancer , 2003, Nature Reviews Cancer.

[26]  Michael Baudis,et al.  Unequivocal delineation of clinicogenetic subgroups and development of a new model for improved outcome prediction in neuroblastoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  Rainer Breitling,et al.  Rank products: a simple, yet powerful, new method to detect differentially regulated genes in replicated microarray experiments , 2004, FEBS letters.

[28]  R. Arceci.  Identification of ALK as the Major Familial Neuroblastoma Predisposition Gene , 2009 .

[29]  R. Tibshirani,et al.  Significance analysis of microarrays applied to the ionizing radiation response , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[30]  Paola Fazi,et al.  Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. , 2005, The New England journal of medicine.

[31]  D. Chung,et al.  Inhibition of neuroblastoma xenograft growth by Hsp90 inhibitors. , 2006, Anticancer research.

[32]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[33]  Holger Christiansen,et al.  Loss of a FYN-regulated differentiation and growth arrest pathway in advanced stage neuroblastoma. , 2002, Cancer cell.

[34]  Antonio Ortega,et al.  Prognostic significance of gene expression profiles of metastatic neuroblastomas lacking MYCN gene amplification. , 2006, Journal of the National Cancer Institute.

[35]  E. Rappaport,et al.  Germline PHOX2B mutation in hereditary neuroblastoma. , 2004, American journal of human genetics.

[36]  R. Stallings,et al.  Correction: Human fetal neuroblast and neuroblastoma transcriptome analysis confirms neuroblast origin and highlights neuroblastoma candidate genes , 2007, Genome Biology.

[37]  F. Baas,et al.  The Phox2B homeobox gene is mutated in sporadic neuroblastomas , 2004, Oncogene.

[38]  R. Tibshirani,et al.  Diagnosis of multiple cancer types by shrunken centroids of gene expression , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[39]  Angelo L. Vescovi,et al.  Brain tumour stem cells , 2006, Nature Reviews Cancer.

[40]  J. Beliakoff,et al.  Hsp90 inhibitors deplete key anti‐apoptotic proteins in pediatric solid tumor cells and demonstrate synergistic anticancer activity with cisplatin , 2005, International journal of cancer.

[41]  Y. Moreau,et al.  Positional gene enrichment analysis of gene sets for high-resolution identification of overrepresented chromosomal regions , 2008, Nucleic acids research.

[42]  Qing-Rong Chen,et al.  Prediction of Clinical Outcome Using Gene Expression Profiling and Artificial Neural Networks for Patients with Neuroblastoma , 2004, Cancer Research.

[43]  G. Mortier,et al.  qBase relative quantification framework and software for management and automated analysis of real-time quantitative PCR data , 2007, Genome Biology.

[44]  Isabelle Janoueix-Lerosey,et al.  Germline mutations of the paired-like homeobox 2B (PHOX2B) gene in neuroblastoma. , 2005, Cancer letters.

[45]  S. Eksborg,et al.  Inhibitors of mammalian target of rapamycin downregulate MYCN protein expression and inhibit neuroblastoma growth in vitro and in vivo , 2008, Oncogene.

[46]  F. Speleman,et al.  Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes , 2002, Genome Biology.

[47]  Jo Vandesompele,et al.  RTPrimerDB: the Real-Time PCR primer and probe database , 2003, Nucleic Acids Res..

[48]  K. Cole,et al.  Neuroblastomas have distinct genomic DNA profiles that predict clinical phenotype and regional gene expression , 2007, Genes, chromosomes & cancer.

[49]  H. Hosoi,et al.  Rapamycin inhibits proliferation of human neuroblastoma cells without suppression of MycN , 2003, International journal of cancer.

[50]  Patrick Warnat,et al.  Customized oligonucleotide microarray gene expression-based classification of neuroblastoma patients outperforms current clinical risk stratification. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.